Trifluoromethoxyl substituted phenylethylene diamines as high affinity σ receptor ligands with potent anti-cocaine actions

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3322-3325

  Smith, Trudy A ^a   Yang, Xiaowen ^a   Wu, Huifang ^a   Pouw, Buddy ^b   Matsumoto, Rae R ^b   Coop, Andrew ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMINE DERIVATIVE; N ETHYL 2 PIPERIDIN 1 YL N [2 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]ETHANAMINE; N ETHYL 2 PYRROLIDIN 1 YL N [2 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]ETHANAMINE; N METHYL 2 PIPERIDIN 1 YL N [2 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]ETHANAMINE; N METHYL 2 PYRROLIDIN 1 YL N [2 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]ETHANAMINE; PHENYLETHYLENE DIAMINE DERIVATIVE; SIGMA 1 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; CONVULSION; DEMETHYLATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ANALYSIS; SWISS WEBSTER MOUSE;

ANIMALS; BRAIN; COCAINE-RELATED DISORDERS; DIAMINES; LIGANDS; MALE; MICE; PHENETHYLAMINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44949223430     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7013666     Document Type: Article

References (24)

1. Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse: Main Findings 1997; Department of Health and Human Services, U.S. Government Printing Office: Washington, DC, 1998.
2. Community Epidemiology Work Group. Epidemiological Trends in Drug Abuse; NIDA, U.S. Government Printing Office: Washington, DC, 1996.
3. Cartwright, W. S. Cocaine medications, cocaine consumption and societal costs. Pharmacoeconomics 2000, 18, 405-413.
4. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 1999, 42, 2721-2736.
5. Newman, A. H. Novel pharmacotherapies for cocaine abuse 1997-2000. Expert Opin. Ther. Pat. 2000, 10, 1095-1122.
6. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237, 1219-1223.
7. Kuhar, M. J.; Ritz, M. C.; Sharkley, J. Cocaine receptors on dopamine transporters mediate cocaine-reinforced behavior. NIDA Res. Monogr. 1988, 88, 14-22.
8. Mittleman, R. E.; Wetli, C. V. Death caused by recreational cocaine use: an update. JAMA, J. Am Med. Assoc. 1984, 252, 1889-1893.
9. Spiehler, V. R.; Reed, D. Brain Concentrations of cocaine and benzoylecgonine in fatal cases. J. Forensic Sci. 1985, 30, 1003-1011.
10. Matsumoto, R. R.; Bowen, W. D.; Su, T. P. Sigma Receptors: Chemistry, Cell Biology, and Clinical Applications; Springer Press: New York, 2007.
11. Martin, W. R.; Eades, G. C.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
12. Quiron, R.; Bowen, W. D.; Itzhak, Y.; Junten, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tarn, S. W.; Taylor, D. P. A. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
13. Booth, R. G.; Wyrick, S. D.; Baldessarini, R. J.; Kula, N. S.; Myers, A. M.; Mailman, R. B. New σ-like receptor recognized by novel phenylaminotetralins: ligand binding and functional studies. Mol. Pharmacol. 1993, 44, 1232-1239.
14. Bowen, W. D.; Hellewell, S. B.; McGarry, K. A. Evidence for a multisite model of the rat brain σ receptor. Eur. J. Pharmacol. 1989, 163, 309-318.
15. 3H]tolyl)guanidine labels more than one site in rat forebrain. Eur. J. Pharmacol. 1992, 217, 149-152.
16. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; William, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268, 9-18.
17. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H.-G.; Striessnig, J.; Kempner, E.; Glossman, H. Purification, molecular cloning, and expression of the mammalian sigma 1-binding site. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-8077.
18. Matsumoto, R. R.; McCracken, K. A.; Friedman, M. J.; Pouw, B.; de Costa, B. R.; Bowen, W. D. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma-1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419, 163-174.
19. Matsumoto, R. R.; Liu, Y.; Lerner, M.; Howard, E. W.; Brackett, D. J. Sigma receptors: potential medications development target for anticocaine agents. Eur. J. Pharmacol. 2003, 469, 1-12.
20. Matasumoto, R. R.; McCraken, M. J.; Pouw, B.; Miller, J.; Bowen, W. D.; Williams, W. E.; de Costa, B. R. N-Alkyl substituted analogs of the σ receptor ligand BD1008 and traditional σ receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur. J. Pharmacol. 2001c, 411, 261-273.
21. Matsumoto, M. M.; Gilmore, D. L.; Pouw, B.; Bowen, W. D.; Williams, W.; Kausar, A.; Coop, A. Novel analogs of the σ receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. Eur. J. Pharmacol. 2004, 492, 21-26.
22. Zhang, Y.; Williams, W.; Bowen, W. D.; Rice, K. C. Synthesis and evaluation of aryl-substituted N-(arylethyl)-N-methyl-2-(1- pyrrolidinyl)ethylamines and corresponding arylacetamides for sigma receptor affinity. J. Med. Chem. 1996, 39, 3564-3568.
23. Brackett, R. L.; Pouw, B.; Blyden, J. F.; Nour, M.; Matsumoto, R. R. Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology. 2000, 39, 407-418.
24. de Costa, B. R.; Radesca, L.; Di Paolo, L.; Bowen, W. D. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2- (pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor. J. Med. Chem. 1992, 35, 38-47.